Johnson & Johnson Price to Sales Ratio 2010-2024 | JNJ
Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of December 20, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-12-20 |
144.47 |
|
4.05 |
| 2024-09-30 |
160.77 |
$35.68 |
4.51 |
| 2024-06-30 |
143.90 |
$34.80 |
4.14 |
| 2024-03-31 |
154.48 |
$33.72 |
4.58 |
| 2023-12-31 |
151.91 |
$32.94 |
4.61 |
| 2023-09-30 |
149.76 |
$29.30 |
5.11 |
| 2023-06-30 |
158.02 |
$28.44 |
5.56 |
| 2023-03-31 |
146.87 |
$29.25 |
5.02 |
| 2022-12-31 |
166.21 |
$30.01 |
5.54 |
| 2022-09-30 |
152.72 |
$28.96 |
5.27 |
| 2022-06-30 |
164.84 |
$30.17 |
5.46 |
| 2022-03-31 |
163.55 |
$29.89 |
5.47 |
| 2021-12-31 |
156.85 |
$29.52 |
5.31 |
| 2021-09-30 |
147.10 |
$33.76 |
4.36 |
| 2021-06-30 |
149.16 |
$31.92 |
4.67 |
| 2020-12-31 |
140.74 |
$30.94 |
4.55 |
| 2020-09-30 |
132.21 |
$30.25 |
4.37 |
| 2020-06-30 |
124.06 |
$30.12 |
4.12 |
| 2020-03-31 |
114.87 |
$30.88 |
3.72 |
| 2019-12-31 |
126.96 |
$30.55 |
4.16 |
| 2019-09-30 |
111.83 |
$30.30 |
3.69 |
| 2019-06-30 |
120.39 |
$29.99 |
4.01 |
| 2019-03-31 |
120.01 |
$30.01 |
4.00 |
| 2018-12-31 |
110.06 |
$29.91 |
3.68 |
| 2018-09-30 |
117.09 |
$29.79 |
3.93 |
| 2018-06-30 |
102.15 |
$29.51 |
3.46 |
| 2018-03-31 |
107.09 |
$28.73 |
3.73 |
| 2017-12-31 |
116.02 |
$27.86 |
4.17 |
| 2017-09-30 |
107.31 |
$26.99 |
3.98 |
| 2017-06-30 |
108.49 |
$26.21 |
4.14 |
| 2017-03-31 |
101.48 |
$25.95 |
3.91 |
| 2016-12-31 |
93.26 |
$25.74 |
3.62 |
| 2016-09-30 |
94.97 |
$25.58 |
3.71 |
| 2016-06-30 |
96.87 |
$27.53 |
3.52 |
| 2016-03-31 |
85.80 |
$27.01 |
3.18 |
| 2015-12-31 |
80.87 |
$27.10 |
2.98 |
| 2021-03-31 |
147.89 |
$26.92 |
5.49 |
| 2015-09-30 |
72.96 |
$24.94 |
2.93 |
| 2015-06-30 |
75.58 |
$25.29 |
2.99 |
| 2015-03-31 |
77.45 |
$25.75 |
3.01 |
| 2014-12-31 |
79.94 |
$25.91 |
3.09 |
| 2014-09-30 |
80.96 |
$25.91 |
3.12 |
| 2014-06-30 |
78.93 |
$25.56 |
3.09 |
| 2014-03-31 |
73.60 |
$24.96 |
2.95 |
| 2013-12-31 |
68.13 |
$24.78 |
2.75 |
| 2013-09-30 |
64.04 |
$24.65 |
2.60 |
| 2013-06-30 |
62.96 |
$24.60 |
2.56 |
| 2013-03-31 |
59.34 |
$24.30 |
2.44 |
| 2012-12-31 |
50.61 |
$24.00 |
2.11 |
| 2012-09-30 |
49.32 |
$23.61 |
2.09 |
| 2012-06-30 |
47.92 |
$23.32 |
2.05 |
| 2012-03-31 |
46.34 |
$23.40 |
1.98 |
| 2011-12-31 |
45.67 |
$23.42 |
1.95 |
| 2011-09-30 |
43.94 |
$23.17 |
1.90 |
| 2011-06-30 |
45.49 |
$22.79 |
2.00 |
| 2011-03-31 |
40.17 |
$22.30 |
1.80 |
| 2010-12-31 |
41.56 |
$22.06 |
1.88 |
| 2010-09-30 |
41.27 |
$22.38 |
1.84 |
| 2010-06-30 |
38.98 |
$22.40 |
1.74 |
| 2010-03-31 |
42.64 |
$22.40 |
1.90 |
| 2009-12-31 |
41.80 |
$22.20 |
1.88 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$345.687B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
